Dyne Therapeutics, Inc.

NasdaqGS DYN

Dyne Therapeutics, Inc. Market Capitalization on January 14, 2025: USD 1.53 B

Dyne Therapeutics, Inc. Market Capitalization is USD 1.53 B on January 14, 2025, a 11.61% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Dyne Therapeutics, Inc. 52-week high Market Capitalization is USD 4.39 B on August 21, 2024, which is 187.57% above the current Market Capitalization.
Dyne Therapeutics, Inc. 52-week low Market Capitalization is USD 1.28 B on January 19, 2024, which is -16.34% below the current Market Capitalization.
Dyne Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 2.83 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGS: DYN

Dyne Therapeutics, Inc.

CEO	Mr. John G. Cox M.B.A.
IPO Date	Sept. 17, 2020
Location	United States
Headquarters	1560 Trapelo Road
Employees	173
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Key trends

Past 5 years